David S. Hilzenrath Former Staff Latest Work Accounting’s Big Lie — and How to Fix It A colossal conflict of interest compromises the auditing of public companies and the financial security of everyone who depends on them. This report provides background on the issue and options for potential reform. October 6, 2022 By David S. Hilzenrath Financial Regulator Flexes Its Weakness A disciplinary action against a former KPMG vice chair shows that the board that polices corporate auditors remains a weak enforcer of its own rules. May 3, 2022 By David S. Hilzenrath At Least Half of Panel Advising Congress on Drug Policy Had Undisclosed Ties to Drug Makers One member was paid $875 per hour to serve as an expert witness for Merck in a lawsuit. October 28, 2021 By David S. Hilzenrath Discarded Drugs: Infrastructure Bill Leaves Cancer Patients by the Wayside The infrastructure bill would require drug companies to repay Medicare — but not Medicare patients — for money spent on medicine that’s thrown away. September 29, 2021 By David S. Hilzenrath What the U.K. Can Learn from the U.S. Experience with Audit Reform: Don’t Do What We Did An Open Letter to the U.K. Government July 7, 2021 By David S. Hilzenrath How Foreign Influence Can Corrupt a President. Legally. Close this loophole. June 7, 2021 By David S. Hilzenrath View all
Accounting’s Big Lie — and How to Fix It A colossal conflict of interest compromises the auditing of public companies and the financial security of everyone who depends on them. This report provides background on the issue and options for potential reform. October 6, 2022 By David S. Hilzenrath
Financial Regulator Flexes Its Weakness A disciplinary action against a former KPMG vice chair shows that the board that polices corporate auditors remains a weak enforcer of its own rules. May 3, 2022 By David S. Hilzenrath
At Least Half of Panel Advising Congress on Drug Policy Had Undisclosed Ties to Drug Makers One member was paid $875 per hour to serve as an expert witness for Merck in a lawsuit. October 28, 2021 By David S. Hilzenrath
Discarded Drugs: Infrastructure Bill Leaves Cancer Patients by the Wayside The infrastructure bill would require drug companies to repay Medicare — but not Medicare patients — for money spent on medicine that’s thrown away. September 29, 2021 By David S. Hilzenrath
What the U.K. Can Learn from the U.S. Experience with Audit Reform: Don’t Do What We Did An Open Letter to the U.K. Government July 7, 2021 By David S. Hilzenrath
How Foreign Influence Can Corrupt a President. Legally. Close this loophole. June 7, 2021 By David S. Hilzenrath
